GlassScriptPhysician profile
Andrew H Lyons
NPI 1982001905
$6,968.90
in general payments reported to CMS, 2019-2025
26 companies · $1,592 in 2025
The $1,592 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $886 · 2022: $2,102 · 2023: $1,095 · 2024: $1,293 · 2025: $1,592.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,981.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,187.79 | 2021-2025 | |
| Corium, LLC | $695.21 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $618.20 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Otsuka America Pharmaceutical, INC. | $582.90 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $551.80 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $452.25 | 2021-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $396.20 | 2021-2024 | Jornay Pm |
| Alkermes, INC. | $384.91 | 2022-2023 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $320.44 | 2021-2025 | Trintellix |
| Lundbeck LLC | $281.78 | 2021-2025 | Rexulti |
| Tris Pharma INC | $253.89 | 2022-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $242.64 | 2021-2024 | Hetlioz, Fanapt |
| Janssen Pharmaceuticals, INC | $184.13 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $176.02 | 2021-2025 | Qelbree, Qelbree |
| Bausch Health US, LLC | $118.43 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $85.83 | 2021 | |
| Vertical Pharmaceuticals, LLC | $77.09 | 2024-2025 | Relexxii |
| Noven Therapeutics, LLC | $73.61 | 2024-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $72.98 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $59.22 | 2022-2025 | Austedo Xr, Austedo Xr |
| Axsome Therapeutics, INC. | $54.50 | 2023-2025 | Sunosi, Auvelity |
| Idorsia Pharmaceuticals US INC | $28.26 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $18.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $18.11 | 2025 | Cobenfy |
| Tempus Ai, INC | $17.80 | 2025 | Tempus Pixel |
| Livanova USA, INC. | $16.21 | 2024 | Vns Therapy Symmetry Model 8103 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.